Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

From PeerVoice Oncology & Haematology Audio by PeerVoice

January 7, 2026 · 22 min

About this episode

Rebecca Dent discusses the rationale and emerging evidence for TROP2-targeted therapies in triple-negative breast cancer.

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

People in this episode

Guest: Rebecca Dent, MD, FRCP

Topics covered

  • TROP2
  • Triple-Negative Breast Cancer
  • Antibody-Drug Conjugates
  • Therapeutic Potential
  • Disease-Stage Settings

Keywords

  • TROP2
  • Triple-Negative Breast Cancer
  • Antibody-Drug Conjugates
  • Therapeutic Potential
  • Cancer Treatment

Mentioned in this episode

Organizations: Canada

Products: TROP2-Targeted Antibody-Drug Conjugates

More episodes of PeerVoice Oncology & Haematology Audio

Explore listener stats, chart rankings, contacts and more on the PeerVoice Oncology & Haematology Audio podcast page.